Statistical Tables (PDF)

Total Page:16

File Type:pdf, Size:1020Kb

Statistical Tables (PDF) STATISTICAL TABLES 㩿㪁㪫㪿㫀㫊㩷㫋㫉㪸㫅㫊㫃㪸㫋㫀㫆㫅㩷㫆㪽㩷㫋㪿㪼㩷㫆㫉㫀㪾㫀㫅㪸㫃㩷㪡㪸㫇㪸㫅㪼㫊㪼㩷㫋㪼㫏㫋㩷㫀㫊㩷㪽㫆㫉㩷㫀㫅㪽㫆㫉㫄㪸㫋㫀㫆㫅㩷㫇㫌㫉㫇㫆㫊㪼㩷㫆㫅㫃㫐㩷㩿㫀㫅㩷㫋㪿㪼㩷㪼㫍㪼㫅㫋㩷㫆㪽㩷㫀㫅㪺㫆㫅㫊㫀㫊㫋㪼㫅㪺㫐㪃㩷㫋㪿㪼㩷㪡㪸㫇㪸㫅㪼㫊㪼㩷㫋㪼㫏㫋㩷㫊㪿㪸㫃㫃㩷㫇㫉㪼㫍㪸㫀㫃㪀㪅 㪙㫌㪻㪾㪼㫋 㪘㫋㫋㪸㪺㪿㫄㪼㫅㫋㩷㪈 㪙㫌㪻㪾㪼㫋㩷㪽㫆㫉㩷㫋㪿㪼㩷㪤㫀㪻㫋㪼㫉㫄㩷㪧㫃㪸㫅㩷㩿㪝㪰㩷㪉㪇㪇㪋㩷㪄㩷㪉㪇㪇㪏㪀 㩿㪬㫅㫀㫋㪑㩷㪤㫀㫃㫃㫀㫆㫅㩷㫐㪼㫅㪀 㪘㫄㫆㫌㫅㫋 㪘㪺㪺㫆㫌㫅㫋 㪚㫃㪸㫊㫊㫀㪽㫀㪺㪸㫋㫀㫆㫅 㪠㫅㪽㪼㪺㫋㫀㫆㫌㫊㪄 㪪㪤㪦㪥㪄 㪟㪠㪭㫇㫆㫊㫀㫋㫀㫍㪼㪆 㪘㪛㪩㩷㪩㪼㫃㫀㪼㪽 㪛㫀㫊㪼㪸㫊㪼 㪩㪼㫍㫀㪼㫎 㪧㪸㫋㫀㪼㫅㫋㫊 㪘㪠㪛㪪㩷㪧㪸㫋㫀㪼㫅㫋㫊 㪫㫆㫋㪸㫃 㪩㪼㫃㫀㪼㪽 㪩㪼㫃㫀㪼㪽 㪩㪼㫃㫀㪼㪽 㪠㫅㪺㫆㫄㪼 㪞㫉㪸㫅㫋㩷㩿㪽㫆㫉㩷㫆㫇㪼㫉㪸㫋㫀㫅㪾㩷㪼㫏㫇㪼㫅㪻㫀㫋㫌㫉㪼㫊㪀 㪊㪃㪌㪋㪊 㪊㪃㪌㪋㪊 㪞㫆㫍㪼㫉㫅㫄㪼㫅㫋㪸㫃㩷㪪㫌㪹㫊㫀㪻㫐 㪐㪏㪐 㪐㪏 㪈㪃㪇㪏㪎 㪚㫆㫄㫄㫀㫊㫊㫀㫆㫅㪼㪻㩷㪦㫇㪼㫉㪸㫋㫀㫆㫅㩷㪠㫅㪺㫆㫄㪼 㪈㪉 㪏㪃㪐㪊㪈 㪊㪃㪍㪐㪉 㪈㪉㪃㪍㪊㪌 㪚㫆㫅㫋㫉㫀㪹㫌㫋㫀㫆㫅㫊㩷㪠㫅㪺㫆㫄㪼 㪈㪋㪃㪋㪎㪏 㪉㪃㪊㪐㪈 㪋㪃㪍㪍㪉 㪉㪈㪃㪌㪊㪈 㪬㫊㪼㫉㪄㪝㪼㪼㩷㪩㪼㫍㪼㫅㫌㪼 㪊㪊㪃㪈㪍㪍 㪊㪊㪃㪈㪍㪍 㪥㫆㫅㪄㪦㫇㪼㫉㪸㫋㫀㫅㪾㩷㪠㫅㪺㫆㫄㪼 㪈㪃㪉㪎㪏 㪌㪍 㪉㪊㪐 㪈 㪈 㪈㪃㪌㪎㪌 㩷㩷㩷㩷㩷㩷㩷㩷㩷㪤㪾㫄㫋㩷㪠㫅㪺㫆㫄㪼 㪈㪃㪉㪍㪇 㪌㪌 㪇 㪇 㪇 㪈㪃㪊㪈㪌 㩷㩷㩷㩷㩷㩷㩷㩷㩷㪤㫀㫊㪺㪼㫃㫃㪸㫅㪼㫆㫌㫊㩷㪠㫅㪺㫆㫄㪼 㪈㪏 㪈 㪉㪊㪐 㪈 㪈 㪉㪍㪇 㪫㫆㫋㪸㫃 㪈㪍㪃㪎㪋㪍 㪉㪃㪌㪋㪋 㪋㪈㪃㪍㪉㪊 㪏㪃㪐㪊㪉 㪊㪃㪍㪐㪊 㪎㪊㪃㪌㪊㪏 㪜㫏㫇㪼㫅㪻㫀㫋㫌㫉㪼 㪦㫇㪼㫉㪸㫋㫀㫅㪾㩷㪜㫏㫇㪼㫅㫊㪼㫊 㪏㪃㪉㪋㪎 㪋㪍㪏 㪈㪍㪃㪎㪌㪐 㪏㪃㪍㪌㪌 㪊㪃㪋㪐㪌 㪊㪎㪃㪍㪉㪋 㪘㪻㫄㫀㫅㫀㫊㫋㫉㪸㫋㫀㫍㪼㩷㪜㫏㫇㪼㫅㫊㪼㫊 㪍㪎㪋 㪍㪉 㪐㪃㪉㪍㪉 㪏㪋 㪋㪐 㪈㪇㪃㪈㪊㪈 㪧㪼㫉㫊㫆㫅㫅㪼㫃㩷㪜㫏㫇㪼㫅㫊㪼㫊 㪈㪃㪊㪋㪉 㪈㪊㪈 㪈㪋㪃㪌㪇㪊 㪈㪐㪊 㪈㪋㪏 㪈㪍㪃㪊㪈㪎 㪫㫆㫋㪸㫃 㪈㪇㪃㪉㪍㪊 㪍㪍㪇 㪋㪇㪃㪌㪉㪋 㪏㪃㪐㪊㪉 㪊㪃㪍㪐㪊 㪍㪋㪃㪇㪎㪉 㪓㪥㫆㫋㪼㪕 㪫㪿㪼㩷㫅㫌㫄㪹㪼㫉㫊㩷㪿㪸㫍㪼㩷㪹㪼㪼㫅㩷㫉㫆㫌㫅㪻㪼㪻㩷㫆㪽㪽㩷㪸㫊㩷㪸㩷㫉㫌㫃㪼㪒㩷㫋㪿㪼㫉㪼㪽㫆㫉㪼㪃㩷㫋㪿㪼㩷㫋㫆㫋㪸㫃㫊㩷㫄㪸㫐㩷㫅㫆㫋㩷㪺㫆㫀㫅㪺㫀㪻㪼㩷㫎㫀㫋㪿㩷㫋㪿㪼㩷㪸㪺㫋㫌㪸㫃㩷㫊㫌㫄㪅 117 㩿㪁㪫㪿㫀㫊㩷㫋㫉㪸㫅㫊㫃㪸㫋㫀㫆㫅㩷㫆㪽㩷㫋㪿㪼㩷㫆㫉㫀㪾㫀㫅㪸㫃㩷㪡㪸㫇㪸㫅㪼㫊㪼㩷㫋㪼㫏㫋㩷㫀㫊㩷㪽㫆㫉㩷㫀㫅㪽㫆㫉㫄㪸㫋㫀㫆㫅㩷㫇㫌㫉㫇㫆㫊㪼㩷㫆㫅㫃㫐㩷㩿㫀㫅㩷㫋㪿㪼㩷㪼㫍㪼㫅㫋㩷㫆㪽㩷㫀㫅㪺㫆㫅㫊㫀㫊㫋㪼㫅㪺㫐㪃㩷㫋㪿㪼㩷㪡㪸㫇㪸㫅㪼㫊㪼㩷㫋㪼㫏㫋㩷㫊㪿㪸㫃㫃㩷㫇㫉㪼㫍㪸㫀㫃㪀㪀㪅 㪠㫅㪺㫆㫄㪼㩷㪸㫅㪻㩷㪜㫏㫇㪼㫅㪻㫀㫋㫌㫉㪼㩷㪧㫃㪸㫅 㪘㫋㫋㪸㪺㪿㫄㪼㫅㫋㩷㪉 㪠㫅㪺㫆㫄㪼㩷㪸㫅㪻㩷㪜㫏㫇㪼㫅㪻㫀㫋㫌㫉㪼㩷㪧㫃㪸㫅㩷㪽㫆㫉㩷㫋㪿㪼㩷㪤㫀㪻㫋㪼㫉㫄㩷㪧㫃㪸㫅㩷㩿㪝㪰㪉㪇㪇㪋㩷㪄㩷㪉㪇㪇㪏㪀 㩿㪬㫅㫀㫋㪑㩷㪤㫀㫃㫃㫀㫆㫅㩷㫐㪼㫅㪀 㪘㫄㫆㫌㫅㫋 㪘㪺㪺㫆㫌㫅㫋 㪚㫃㪸㫊㫊㫀㪽㫀㪺㪸㫋㫀㫆㫅 㪠㫅㪽㪼㪺㫋㫀㫆㫌㫊㪄 㪪㪤㪦㪥㪄 㪟㪠㪭㩷㪧㫆㫊㫀㫋㫀㫍㪼㪆 㪘㪛㪩㩷㪩㪼㫃㫀㪼㪽 㪛㫀㫊㪼㪸㫊㪼 㪩㪼㫍㫀㪼㫎 㪧㪸㫋㫀㪼㫅㫋㫊 㪘㪠㪛㪪㩷㪧㪸㫋㫀㪼㫅㫋㫊 㪫㫆㫋㪸㫃 㪩㪼㫃㫀㪼㪽 㪩㪼㫃㫀㪼㪽 㪩㪼㫃㫀㪼㪽 㪜㫏㫇㪼㫅㪻㫀㫋㫌㫉㪼㫊 㪏㪇㪃㪊㪐㪋 㪈㪃㪐㪍㪌 㪊㪏㪃㪌㪉㪊 㪏㪃㪐㪊㪉 㪊㪃㪍㪐㪊 㪈㪊㪊㪃㪌㪇㪎 䇭㪦㫉㪻㫀㫅㪸㫉㫐㩷㪜㫏㫇㪼㫅㫊㪼㫊 㪏㪇㪃㪊㪐㪋 㪈㪃㪐㪍㪌 㪊㪏㪃㪌㪉㪊 㪏㪃㪐㪊㪉 㪊㪃㪍㪐㪊 㪈㪊㪊㪃㪌㪇㪎 㪩㪼㫃㫀㪼㪽㩷㪙㪼㫅㪼㪽㫀㫋㫊 㪎㪃㪋㪏㪏 㪉㪍㪍 㪎㪃㪎㪌㪋 㪟㪼㪸㫃㫋㪿㩷㪸㫅㪻㩷㪮㪼㫃㪽㪸㫉㪼㩷㪦㫇㪼㫉㪸㫋㫀㫅㪾㩷㪜㫏㫇㪼㫅㫊㪼㫊 㪏㪊 㪏㪊 㪩㪼㫍㫀㪼㫎㩷㪦㫇㪼㫉㪸㫋㫀㫅㪾㩷㪚㫆㫊㫋 㪈㪈㪃㪌㪏㪈 㪈㪈㪃㪌㪏㪈 㪪㪸㪽㪼㫋㫐㩷㪤㪼㪸㫊㫌㫉㪼㫊㩷㪦㫇㪼㫉㪸㫋㫀㫅㪾㩷㪚㫆㫊㫋 㪊㪃㪉㪋㪉 㪊㪃㪉㪋㪉 㪙㪼㫅㪼㪽㫀㫋㫊㩿㪟㪼㪸㫃㫋㪿㪺㪸㫉㪼㩷㪘㫃㫃㫆㫎㪸㫅㪺㪼㪃㩷㪼㫋㪺㪅㪀 㪏㪃㪌㪐㪋 㪏㪃㪌㪐㪋 㪙㪼㫅㪼㪽㫀㫋㫊㩷㩿㪪㫇㪼㪺㫀㪸㫃㩷㪘㫃㫃㫆㫎㪸㫅㪺㪼㪃㩷㪼㫋㪺㪅㪀 㪈㪃㪋㪈㪎 㪈㪃㪋㪈㪎 㪩㪼㫊㪼㪸㪺㪿㩷㪸㫅㪻㩷㪪㫋㫌㪻㫐㩷㪦㫇㪼㫉㪸㫋㫀㫅㪾㩷㪚㫆㫊㫋 㪈㪃㪐㪏㪊 㪈㪃㪐㪏㪊 㪘㪻㫄㫀㫅㫀㫊㫋㫉㪸㫋㫀㫍㪼㩷㪜㫏㫇㪼㫅㫊㪼㫊 㪈㪃㪋㪌㪈 㪉㪌㪎 㪐㪃㪉㪊㪊 㪈㪌㪇 㪈㪋㪋 㪈㪈㪃㪉㪊㪌 㪧㪼㫉㫊㫆㫅㫅㪼㫃㩷㪜㫏㫇㪼㫅㫊㪼㫊 㪈㪃㪉㪊㪈 㪈㪊㪈 㪈㪋㪃㪊㪎㪍 㪈㪏㪎 㪈㪋㪍 㪈㪍㪃㪇㪎㪈 㪛㪼㫇㫉㪼㪺㫀㪸㫋㫀㫆㫅㩷㪜㫏㫇㪼㫅㫊㪼㫊 㪈㪋 㪏㪍 㪇 㪇 㪈㪇㪇 㪧㫉㫆㫍㫀㫊㫀㫆㫅㩷㪽㫆㫉㩷㪣㫀㪸㪹㫀㫃㫀㫋㫐㩷㪩㪼㫊㪼㫉㫍㪼 㪎㪇㪃㪈㪈㪍 㪈㪃㪊㪇㪌 㪎㪈㪃㪋㪉㪈 㪥㫆㫅㪄㫆㫇㪼㫉㪸㫋㫀㫅㪾㩷㪜㫏㫇㪼㫅㫊㪼㫊 㪏㪋㪌 㪈㪎 㪠㫅㪺㫆㫄㪼 㪏㪊㪃㪋㪊㪍 㪊㪃㪋㪇㪍 㪊㪏㪃㪌㪊㪎 㪏㪃㪐㪊㪉 㪊㪃㪍㪐㪊 㪈㪊㪏㪃㪇㪇㪋 䇭䇭㪦㫉㪻㫀㫅㪸㫉㫐㩷㪠㫅㪺㫆㫄㪼 㪏㪊㪃㪋㪊㪍 㪊㪃㪋㪇㪍 㪊㪏㪃㪌㪊㪎 㪏㪃㪐㪊㪉 㪊㪃㪍㪐㪊 㪈㪊㪏㪃㪇㪇㪋 㪠㫅㪺㫆㫄㪼㩷㪽㫉㫆㫄㩷㪚㫆㫅㫋㫉㫀㪹㫌㫋㫀㫆㫅㫊 㪈㪋㪃㪋㪎㪏 㪉㪃㪊㪐㪈 㪋㪃㪍㪍㪉 㪉㪈㪃㪌㪊㪈 㪞㫆㫍㪼㫉㫅㫄㪼㫅㫋㪸㫃㩷㪪㫌㪹㫊㫀㪻㫐 㪐㪏㪐 㪐㪏 㪈㪃㪇㪏㪎 㪬㫊㪼㫉㪄㪝㪼㪼㩷㪠㫅㪺㫆㫄㪼 㪊㪇㪃㪇㪎㪎 㪊㪇㪃㪇㪎㪎 㪚㫆㫄㫄㫀㫊㫊㫀㫆㫅㪼㪻㩷㪦㫇㪼㫉㪸㫋㫀㫆㫅㩷㪠㫅㪺㫆㫄㪼 㪈㪉 㪏㪃㪐㪊㪈 㪊㪃㪍㪐㪉 㪈㪉㪃㪍㪊㪌 㪩㪼㫍㪼㫉㫊㪸㫃㩷㫆㪽㩷㪘㫊㫊㪼㫋㩷㪦㪽㪽㫊㪼㫋㩷㪪㫌㪹㫊㫀㪻㫀㪼㫊 㪌㪎 㪈㪉 㪩㪼㫍㪼㫉㫊㪸㫃㩷㫆㪽㩷㪘㫊㫊㪼㫋㩷㪦㪽㪽㫊㪼㫋㩷㪞㫉㪸㫅㫋㫊 㪈㪈 㪞㫉㪸㫅㫋㩷㪽㫆㫉㩷㪦㫇㪼㫉㪸㫋㫀㫅㪾㩷㪜㫏㫇㪼㫅㪻㫀㫋㫌㫉㪼㫊 㪊㪃㪌㪊㪏 㪊㪃㪌㪊㪏 㪩㪼㫍㪼㫉㫊㪸㫃㩷㫆㪽㩷㪣㫀㪸㪹㫀㫃㫀㫋㫐㩷㪩㪼㫊㪼㫉㫍㪼 㪍㪍㪃㪌㪐㪏 㪏㪍㪉 㪍㪎㪃㪋㪍㪇 㪥㫆㫅㪄㫆㫇㪼㫉㪸㫋㫀㫅㪾㩷㪠㫅㪺㫆㫄㪼 㪈㪃㪊㪍㪌 㪌㪍 㪉㪋㪇 㪈 㪈 㪈㪃㪍㪍㪊 㪥㪼㫋㩷㪠㫅㪺㫆㫄㪼䋨䂦㪥㪼㫋㩷㪣㫆㫊㫊䋩 㪊㪃㪇㪋㪉 㪈㪃㪋㪋㪈 㪈㪌 㪇 㪇 㪋㪃㪋㪐㪏 㪩㪼㫍㪼㫉㫊㪸㫃㩷㫆㪽㩷㪘㫇㫇㫉㫆㫇㫉㫀㪸㫋㪼㪻㩷㪪㫌㫉㫇㫃㫌㫊 㪇㪇㪇㪇㪇㪇 㪞㫉㫆㫊㫊㩷㪠㫅㪺㫆㫄㪼䋨䂦㪞㫉㫆㫊㫊㩷㪣㫆㫊㫊䋩 㪊㪃㪇㪋㪉 㪈㪃㪋㪋㪈 㪈㪌 㪇 㪇 㪋㪃㪋㪐㪏 㪓㪥㫆㫋㪼㩷㪈㪕 㪫㪿㪼㩷㪾㫉㪸㫅㫋㩷㩿㪽㫆㫉㩷㫆㫇㪼㫉㪸㫋㫀㫅㪾㩷㪼㫏㫇㪼㪻㫀㫋㫌㫉㪼㫊㪀㩷㫀㫊㩷㪸㫊㫊㫌㫄㪼㪻㩷㫋㫆㩷㪹㪼㩷㫋㪿㪼㩷㫉㪼㫊㫆㫌㫉㪺㪼㩷㪽㫆㫉㩷㫉㪼㫋㫀㫉㪼㫄㪼㫅㫋㩷㪸㫃㫃㫆㫎㪸㫅㪺㪼㩷㪽㫆㫉㩷㫋㪿㫆㫊㪼㩷㫊㫋㪸㪽㪽㩷㫄㪼㫄㪹㪼㫉㫊㩷㫋㪿㪸㫋㩷㫇㪼㫉㫋㪸㫀㫅㩷㩷 㫋㫆㩷㫋㪿㪼㩷㫆㫇㪼㫉㪸㫋㫀㫆㫅㩷㪸㪻㪻㫉㪼㫊㫊㪼㪻㩷㪹㫐㩷㫋㪿㪼㩷㪾㫉㪸㫅㫋㩷㫌㫅㪻㪼㫉㩷㫋㪿㪼㩷㪩㪼㫍㫀㪼㫎㩷㪘㪺㪺㫆㫌㫅㫋㪅 㪟㫆㫎㪼㫍㪼㫉㪃㩷㫋㪿㫀㫊㩷㪼㫏㪺㫃㫌㪻㪼㫊㩷㫋㪿㪼㩷㪸㫄㫆㫌㫅㫋㩷㫋㪿㪸㫋㩷㪿㪸㫊㩷㪹㪼㪼㫅㩷㪸㫉㫉㪸㫅㪾㪼㪻㩷㪹㫐㩷㪾㫉㪸㫅㫋㩷㩿㪽㫆㫉㩷㫆㫇㪼㫉㪸㫋㫀㫅㪾㩷㪼㫏㫇㪼㫅㪻㫀㫋㫌㫉㪼㫊㪀㩷㪸㫊㩷㪸㩷㫉㪼㫋㫀㫉㪼㫄㪼㫅㫋㩷㪸㫃㫃㫆㫎㪸㫅㪺㪼㩷 㪼㫈㫌㫀㫍㪸㫃㪼㫅㫋㩷㫋㫆㩷㫆㫅㪼㩾㫊㩷㫋㪼㫅㫌㫉㪼㪃㩷㪸㫊㩷㫀㫅㪻㫀㪺㪸㫋㪼㪻㩷㫌㫅㪻㪼㫉㩷㪘㫉㫋㫀㪺㫃㪼㩷㪏㪃㩷㪧㪸㫉㪸㪾㫉㪸㫇㪿㩷㪉㩷㫆㪽㩷㫊㫌㫇㫇㫃㪼㫄㪼㫅㫋㪸㫉㫐㩷㫇㫉㫆㫍㫀㫊㫀㫆㫅㪅 㪓㪥㫆㫋㪼㩷㪉㪕 㪫㪿㪼㩷㫅㫌㫄㪹㪼㫉㫊㩷㪿㪸㫍㪼㩷㪹㪼㪼㫅㩷㫉㫆㫌㫅㪻㪼㪻㩷㫆㪽㪽㩷㪸㫊㩷㪸㩷㫉㫌㫃㪼㪒㩷㫋㪿㪼㫉㪼㪽㫆㫉㪼㪃㩷㫋㪿㪼㩷㫋㫆㫋㪸㫃㫊㩷㫄㪸㫐㩷㫅㫆㫋㩷㪺㫆㫀㫅㪺㫀㪻㪼㩷㫎㫀㫋㪿㩷㫋㪿㪼㩷㪸㪺㫋㫌㪸㫃㩷㫊㫌㫄㪅 118 㩿㪁㪫㪿㫀㫊㩷㫋㫉㪸㫅㫊㫃㪸㫋㫀㫆㫅㩷㫆㪽㩷㫋㪿㪼㩷㫆㫉㫀㪾㫀㫅㪸㫃㩷㪡㪸㫇㪸㫅㪼㫊㪼㩷㫋㪼㫏㫋㩷㫀㫊㩷㪽㫆㫉㩷㫀㫅㪽㫆㫉㫄㪸㫋㫀㫆㫅㩷㫇㫌㫉㫇㫆㫊㪼㩷㫆㫅㫃㫐㩷㩿㫀㫅㩷㫋㪿㪼㩷㪼㫍㪼㫅㫋㩷㫆㪽㩷㫀㫅㪺㫆㫅㫊㫀㫊㫋㪼㫅㪺㫐㪃㩷㫋㪿㪼㩷㪡㪸㫇㪸㫅㪼㫊㪼㩷㫋㪼㫏㫋㩷㫊㪿㪸㫃㫃㩷㫇㫉㪼㫍㪸㫀㫃㪀㪀㪅 㪚㪸㫊㪿㩷㪝㫃㫆㫎㫊㩷㪧㫃㪸㫅 㪘㫋㫋㪸㪺㪿㫄㪼㫅㫋㩷㪊 㪚㪸㫊㪿㩷㪝㫃㫆㫎㫊㩷㪧㫃㪸㫅㩷㪽㫆㫉㩷㫋㪿㪼㩷㪤㫀㪻㫋㪼㫉㫄㩷㪧㫃㪸㫅㩷㩿㪝㪰㪉㪇㪇㪋㩷㪄㩷㪉㪇㪇㪏㪀 䇭䇭㩿㪬㫅㫀㫋㪑㩷㪤㫀㫃㫃㫀㫆㫅㩷㪰㪼㫅㪀 㪘㫄㫆㫌㫅㫋 㪘㪺㪺㫆㫌㫅㫋 㪚㫃㪸㫊㫊㫀㪽㫀㪺㪸㫋㫀㫆㫅 㪠㫅㪽㪼㪺㫋㫀㫆㫌㫊㪄 㪪㪤㪦㪥㪄 㪟㪠㪭㩷㪧㫆㫊㫀㫋㫀㫍㪼㪆 㪘㪛㪩㩷㪩㪼㫃㫀㪼㪽 㪛㫀㫊㪼㪸㫊㪼 㪩㪼㫍㫀㪼㫎 㪧㪸㫋㫀㪼㫅㫋㫊 㪘㪠㪛㪪㩷㪧㪸㫋㫀㪼㫅㫋㫊 㪫㫆㫋㪸㫃 㪩㪼㫃㫀㪼㪽 㪩㪼㫃㫀㪼㪽 㪩㪼㫃㫀㪼㪽 㪚㪸㫊㪿㩷㪦㫌㫋㪽㫃㫆㫎㫊 㩷㪚㪸㫊㪿㩷㪦㫌㫋㪽㫃㫆㫎㫊㩷㪽㫉㫆㫄㩷㪦㫇㪼㫉㪸㫋㫀㫅㪾㩷㪘㪺㫋㫀㫍㫀㫋㫀㪼㫊 㪈㪇㪃㪈㪌㪉 㪍㪌㪐 㪋㪇㪃㪋㪎㪉 㪏㪃㪐㪉㪍 㪊㪃㪍㪐㪉 㪍㪊㪃㪐㪇㪈 㪩㪼㫃㫀㪼㪽㩷㪙㪼㫅㪼㪽㫀㫋㫊 㪎㪃㪋㪏㪏 㪉㪍㪍 㪎㪃㪎㪌㪋 㪟㪼㪸㫃㫋㪿㩷㪸㫅㪻㩷㪮㪼㫃㪽㪸㫉㪼㩷㪦㫇㪼㫉㪸㫋㫀㫅㪾㩷㪜㫏㫇㪼㫅㫊㪼㫊 㪏㪊 㪏㪊 㪙㪼㫅㪼㪽㫀㫋㫊㩷㩿㪟㪼㪸㫃㫋㪿㪺㪸㫉㪼㩷㪘㫃㫃㫆㫎㪸㫅㪺㪼㪃㩷㪼㫋㪺㪅㪀 㪏㪃㪌㪐㪋 㪏㪃㪌㪐㪋 㪙㪼㫅㪼㪽㫀㫋㫊㩷㩿㪪㫇㪼㪺㫀㪸㫃㩷㪘㫃㫃㫆㫎㪸㫅㪺㪼㪃㩷㪼㫋㪺㪅㪀 㪈㪃㪋㪈㪎 㪈㪃㪋㪈㪎 㪩㪼㫊㪼㪸㪺㪿㩷㩽㩷㪪㫋㫌㪻㫐㩷㪦㫇㪼㫉㪸㫋㫀㫅㪾㩷㪜㫏㫇㪼㫅㫊㪼㫊 㪈㪃㪐㪏㪊 㪈㪃㪐㪏㪊 㪘㪻㫄㫀㫅㫀㫊㫋㫉㪸㫋㫀㫍㪼㩷㪜㫏㫇㪼㫅㫊㪼㫊 㪈㪃㪊㪋㪇 㪉㪌㪎 㪐㪃㪉㪍㪉 㪈㪋㪋 㪈㪋㪊 㪈㪈㪃㪈㪋㪍 㪧㪼㫉㫊㫆㫅㫅㪼㫃㩷㪜㫏㫇㪼㫅㫊㪼㫊 㪈㪃㪉㪊㪈 㪈㪊㪈 㪈㪋㪃㪋㪌㪈 㪈㪏㪎 㪈㪋㪍 㪈㪍㪃㪈㪋㪍 㪩㪼㪽㫌㫅㪻 㪋㪋 㪏 㪤㫀㫊㪺㪼㫃㫃㪸㫅㪼㫆㫌㫊 㪊㪌 㪏 㩷㪚㪸㫊㪿㩷㪦㫌㫋㪽㫃㫆㫎㫊㩷㪽㫉㫆㫄㩷㪠㫅㫍㪼㫊㫋㫀㫅㪾㩷㪘㪺㫋㫀㫍㫀㫋㫀㪼㫊 㪌㪃㪏㪍㪐 㪌㪃㪏㪍㪐 㩷㪚㪸㫊㪿㩷㪦㫌㫋㪽㫃㫆㫎㫊㩷㪽㫉㫆㫄㩷㪝㫀㫅㪸㫅㪺㫀㪸㫃㩷㪘㪺㫋㫀㫍㫀㫋㫀㪼㫊㩷 㪈㪏 㪌㪈 㪈 㪈 㪎㪈 㩷㪘㫄㫆㫌㫅㫋㩷㪺㪸㫉㫉㫀㪼㪻㩷㪽㫎㪻㩷㫋㫆㩷㫋㪿㪼㩷㫅㪼㫏㫋㩷㪤㫀㪻㫋㪼㫉㫄㩷㪧㪼㫉㫀㫆㪻 㪉㪍㪃㪉㪌㪈 㪌㪃㪍㪈㪉 㪐㪃㪍㪊㪐 㪉㪉㪎 㪎㪊㪉 㪋㪉㪃㪋㪍㪈 㪫㫆㫋㪸㫃 㪋㪉㪃㪉㪐㪉 㪍㪃㪉㪎㪉 㪌㪇㪃㪈㪍㪊 㪐㪃㪈㪌㪍 㪋㪃㪋㪉㪋 㪈㪈㪉㪃㪊㪇㪎 㪚㪸㫊㪿㩷㪠㫅㪽㫃㫆㫎㫊 㩷㪚㪸㫊㪿㩷㪠㫅㪽㫃㫆㫎㫊㩷㪽㫉㫆㫄㩷㪦㫇㪼㫉㪸㫋㫀㫅㪾㩷㪘㪺㫋㫀㫍㫀㫋㫀㪼㫊 㪈㪌㪃㪋㪏㪌 㪉㪃㪋㪏㪐 㪋㪈㪃㪍㪉㪊 㪏㪃㪐㪊㪉 㪊㪃㪍㪐㪊 㪎㪉㪃㪉㪉㪉 㪩㪼㫃㫀㪼㪽㩷㪙㪼㫅㪼㪽㫀㫋㫊 㪈㪋㪃㪋㪎㪏 㪉㪃㪊㪐㪈 㪋㪃㪍㪍㪉 㪉㪈㪃㪌㪊㪈 㪞㫉㪸㫅㫋 㪊㪃㪌㪋㪊 㪊㪃㪌㪋㪊 㪞㫆㫍㪼㫉㫅㫄㪼㫅㫋㩷㪪㫌㪹㫊㫀㪻㫐 㪐㪏㪐 㪐㪏 㪈㪃㪇㪏㪎 㪬㫊㪼㫉㪄㪝㪼㪼㩷㪠㫅㪺㫆㫄㪼 㪊㪊㪃㪈㪍㪍 㪊㪊㪃㪈㪍㪍 㪚㫆㫄㫄㫀㫊㫊㫀㫆㫅㪼㪻㩷㪦㫇㪼㫉㪸㫋㫀㫆㫅㩷㪠㫅㪺㫆㫄㪼 㪈㪉 㪏㪃㪐㪊㪈 㪊㪃㪍㪐㪉 㪈㪉㪃㪍㪊㪌 㪤㫀㫊㪺㪼㫃㫃㪸㫅㪼㫆㫌㫊㩷㪠㫅㪺㫆㫄㪼 㪈㪏 㪈 㪉㪊㪐 㪈 㪈 㪉㪍㪇 䇭㪚㪸㫊㪿㩷㪠㫅㪽㫃㫆㫎㫊㩷㪽㫉㫆㫄㩷㪠㫅㫍㪼㫊㫋㫀㫅㪾㩷㪘㪺㫋㫀㫍㫀㫋㫀㪼㫊 㪈㪃㪉㪌㪐 㪌㪌 㪈㪃㪊㪈㪋 䇭㪚㪸㫊㪿㩷㪠㫅㪽㫃㫆㫎㫊㩷㪽㫉㫆㫄㩷㪝㫀㫅㪸㫅㪺㫀㪸㫃㩷㪘㪺㫋㫀㫍㫀㫋㫀㪼㫊㩷 㪋㪃㪐㪊㪋 㪌㪈 㪈 㪈 㪋㪃㪐㪏㪎 䇭㪘㫄㫆㫌㫅㫋㩷㪹㫉㫆㫌㪾㪿㫋㩷㪽㫎㪻㩷㪸㫋㩷㫋㪿㪼㩷㪹㪼㪾㫀㫅㫅㫀㫅㪾㩷㫆㪽㩷㪸㩷㫇㪼㫉㫀㫆㪻㩷 㪉㪇㪃㪍㪈㪉 㪊㪃㪎㪉㪏 㪏㪃㪋㪏㪐 㪉㪉㪉 㪎㪊㪇 㪊㪊㪃㪎㪏㪈 㩷㩷㩷㩿㪻㫌㫉㫀㫅㪾㩷㫋㪿㪼㩷㪤㫀㪻㫋㪼㫉㫄㩷㪧㫃㪸㫅㩷㫇㪼㫉㫀㫆㪻㪀 㪫㫆㫋㪸㫃 㪋㪉㪃㪉㪐㪉 㪍㪃㪉㪎㪉 㪌㪇㪃㪈㪍㪊 㪐㪃㪈㪌㪍 㪋㪃㪋㪉㪋 㪈㪈㪉㪃㪊㪇㪎 㪓㪥㫆㫋㪼㪕 㪫㪿㪼㩷㪽㫀㪾㫌㫉㪼㫊㩷㪿㪸㫍㪼㩷㪹㪼㪼㫅㩷㫉㫆㫌㫅㪻㪼㪻㩷㫆㪽㪽㩷㪸㫊㩷㪸㩷㫉㫌㫃㪼㪒㩷㫋㪿㪼㫉㪼㪽㫆㫉㪼㪃㩷㫋㪿㪼㩷㫋㫆㫋㪸㫃㫊㩷㫄㪸㫐㩷㫅㫆㫋㩷㪺㫆㫀㫅㪺㫀㪻㪼㩷㫎㫀㫋㪿㩷㫋㪿㪼㩷㪸㪺㫋㫌㪸㫃㩷㫊㫌㫄㪅 119 Adverse Health Effect Relief Services Table 1: Number of Cases on Adverse Health Effect Relief Benefits 1980-2004 Classification Number of Number of Number of Number of Fiscal year Claims Withdrawals Payments Non-payments 1980 20 䋨 20 䋩 0 䋨 0 䋩 8 䋨 8 䋩 2 䋨 2 䋩 1981 35 䋨 29 䋩 1 䋨 1 䋩 20 䋨 17 䋩 1 䋨 1 䋩 1982 78 䋨 66 䋩 6 䋨 6 䋩 38 䋨 28 䋩 8 䋨 8 䋩 1983 78 䋨 66 䋩 2 䋨 2 䋩 62 䋨 48 䋩 8 䋨 8 䋩 1984 130 䋨 105 䋩 1 䋨 1 䋩 62 䋨 53 䋩 20 䋨 15 䋩 1985 115 䋨 89 䋩 2 䋨 2 䋩 95 䋨 73 䋩 23 䋨 16 䋩 1986 133 䋨 104 䋩 0 䋨 0 䋩 98 䋨 82 䋩 19 䋨 13 䋩 1987 136 䋨 107 䋩 0 䋨 0 䋩 84 䋨 65 䋩 24 䋨 13 䋩 1988 175 䋨 142 䋩 2 䋨 2 䋩 120 䋨 102 䋩 20 䋨 13 䋩 1989 208 䋨 176 䋩 1 䋨 1 䋩 137 䋨 119 䋩 19 䋨 16 䋩 1990 225 䋨 183 䋩 0 䋨 0 䋩 226 䋨 197 䋩 44 䋨 30 䋩 1991 208 䋨 168 䋩 0 䋨 0 䋩 194 䋨 152 䋩 46 䋨 33 䋩 1992 203 䋨 173 䋩 4 䋨 4 䋩 199 䋨 170 䋩 41 䋨 30 䋩 1993 202 䋨 169 䋩 3 䋨 3 䋩 176 䋨 157 䋩 32 䋨 27 䋩 1994 205 䋨 166 䋩 3 䋨 3 䋩 195 䋨 165 䋩 35 䋨 24 䋩 1995 217 䋨 167 䋩 1 䋨 1 䋩 172 䋨 139 䋩 25 䋨 14 䋩 1996 297 䋨 246 䋩 2 䋨 2 䋩 190 䋨 158 䋩 49 䋨 33 䋩 1997 399 䋨 330 䋩 0 䋨 0 䋩 294 䋨 238 䋩 55 䋨 49 䋩 1998 361 䋨 300 䋩 0 䋨 0 䋩 306 䋨 261 䋩 49 䋨 40 䋩 1999 389 䋨 318 䋩 3 䋨 2 䋩 289 䋨 238 䋩 46 䋨 41 䋩 2000 480 䋨 414 䋩 0 䋨 0 䋩 343 䋨 293 䋩 61 䋨 54 䋩 2001 483 䋨 411 䋩 0 䋨 0 䋩 352 䋨 294 䋩 64 䋨 54 䋩 2002 629 䋨 531 䋩 0 䋨 0 䋩 352 䋨 288 䋩 79 䋨 66 䋩 2003 793 䋨 702 䋩 2 䋨 2 䋩 465 䋨 407 䋩 99 䋨 82 䋩 2004 769 䋨 675 䋩 1 䋨 1 䋩 513 䋨 460 䋩 119 䋨 101 䋩 Total 6,968 䋨 5,857 䋩 34 䋨 33 䋩 4,990 䋨 4,212 䋩 988 䋨 783 䋩 (Note) The number of cases indicates the number of all the claims reported to PMDA. The number includes even multiple claims done by the same claimants for the same reason. The number in the parentheses indicates the number of all the claimants. The number excludes their reclaims done for the same reason. 120 Table 2: Number of claims and benefit amounts in Adverse Health Effect Relief Services Medical expenses Medical allowance Disability pension Pension for raising handicapped children Fiscal year Number Number Number Number Number Number Number Number Number Number Number Number Benefit Benefit Benefit Benefit of of of non- of of of non- of of of non- of of of non- amounts amounts amounts amounts claims payment payments claims payments payments claims payments payments claims payments payments (Cases) (Cases) (Cases) (Thousand yen) (Cases) (Cases) (Cases) (Thousand yen) (Cases) (Cases) (Cases) (Thousand yen) (Cases) (Cases) (Cases) (Thousand yen) 1980 17 6 1 292 18 7 1 315 0 0 0 0 0 0 0 0 1981 16 12 1 707 30 17 1 1,308 3 1 0 632 0 0 0 0 1982 26 14 3 1,369 59 28 5 3,647 16 5 3 7,687 0 0 0 0 1983 31 26 2 2,201 61 51 4 7,774 12 4 4 19,094 0 0 0 0 1984 69 28 6 2,947 99 53 13 6,246 22 8 8 33,858 4 0 0 0 1985 69 46 16 6,443 90 72 19 11,891 20 4 9 39,082 0 2 1 1,382 1986 83 61 13 5,937 99 77 12 8,888 17 7 14 53,820 4 1 0 2,647 1987 98 55 11 6,109 122 76 14 10,422 9 9 9 81,209 0 1 1 2,825 1988 107 83 9 9,201 135 105 10 11,924 26 9 2 101,206 6 0 1 2,715 1989 131 90 8 10,890 175 109 12 11,901 20 8 4 105,448 5 2 2 3,506 1990 167 167 17 16,990 185 204 25 22,736 29 10 26 124,128 0 3 5 6,516 1991 148 147 25 15,539 171 167 32 22,631 27 17 15 144,466 2 1 0 5,439 1992 153 149 24 17,156 173 165 26 19,463 21 13 13 167,235 1 2 0 6,326 1993 142 128 16 16,521 166 149 21 16,760 27 11 15 190,711 3 0 1 5,254 1994 155 156 23 18,027 184 177 29 20,055 27 14 17 218,198 1 3 0 6,121 1995 138 122 16 11,775 167 150 18 16,355 36 16 12 245,773 3 0 1 5,666 1996 193 130 25 12,749 239 161 27 19,381 39 18 18 281,838 2 1 2 5,525 1997 283 209 27 24,180 328 252 33 28,114 51 25 23 326,985 7 1 2 3,824 1998 241 226 26 21,456 286 260 28 24,657 36 23 23 385,285 2 2 3 5,647 1999 258 206 20 20,391 327 246 29 26,294 40 11 13 389,353 5 4 0 10,736 2000 321 229 22 21,128 411 305 36 30,496 53 22 19 435,484 3 3 1 11,374 2001 334 252 37 22,541 398 302 48 33,406 35 28 24 483,316 9 4 0 12,226 2002 474 237 54 21,049 533 293 64 30,654 67 24 17 504,134 2 4 0 17,352 2003 640 367 60 34,813 683 408 65 35,388 68 22 27 552,869 9 2 1 16,991 2004 613 448 74 51,722 650 472 80 42,711 73 24 33 592,028 14 4 0 17,810 Total 4,907 3,594 536 372,133 5,789 4,306 652 463,417 774 333 348 5,483,839 82 40 21 149,882 (Note) 1. The number of claims shown in this table indicates one case per payment type, which does not correspond to those in Table 1.
Recommended publications
  • Management of Cutaneous Hemangiomas in Pediatric Patients
    PEDIATRIC DERMATOLOGY Series Editor: Camila K. Janniger, MD Management of Cutaneous Hemangiomas in Pediatric Patients Maria Letizia Musumeci, MD, PhD; Karina Schlecht, MD, PhD; Rosario Perrotta, MD; Robert A. Schwartz, MD, MPH; Giuseppe Micali, MD Cutaneous hemangiomas (CHs) are common benign during the first year of life and slow involution that vascular tumors of childhood. Clinically, they are usually is completed by 5 to 10 years of age.1 For characterized by a typical evolution profile, consist- this reason, no treatment is necessary in most cases. ing of a rapid proliferation during the first year of However, when CHs are located in areas at risk for life and slow involution that usually is completed functional complications; are of considerable size; or by 5 to 10 years of age. In most cases, no treat- repeatedly undergo bleeding, ulceration, or superin- ment is necessary. However, when CHs are located fection, a prompt and adequate treatment approach in areas at risk for functional complications; are of is required.2 considerable size; or repeatedly undergo bleeding, ulceration, or superinfection, a prompt and adequate Epidemiology treatment approach is required. First-line approaches CHs are present in 1.0% to 2.6% of neonates and in include topical, intralesional, and systemic corti- 10% to 12% of infants by 12 months of age.3 Thirty costeroids. Second-line options include interferon percent of CHs are first evident at birth; the remain- alfa-2a and -2b, laser therapy, and surgical therapy. der appear during the second month of life. The Third-line approaches include cytotoxins, emboliza- frequency of these benign tumors increases in pre- tion, and angiogenesis inhibitors.
    [Show full text]
  • Pharmaceuticals and Medical Devices Safety Information No
    Pharmaceuticals and Medical Devices Safety Information No. 203 July 2004 Table of Contents 1. Serious skin disorders caused by pharmaceuticals ···················3 2. Effects of electromagnetic waves from antitheft devices, etc. on medical devices ······································7 3. Important Safety Information ··························································· 13 .1. Monoethanolamine Oleate ······························································· 13 .2. Clarithromycin ··················································································16 .3. Tegafur/Gimeracil/Oteracil Potassium ·············································· 22 .4. Melphalan (injectable dosage form) ················································· 25 4. Revision of PRECAUTIONS (No. 157) Milnacipran Hydrochloride (and 6 others) ···················································30 This Pharmaceuticals and Medical Devices Safety Information (PMDSI) is issued based on safety information collected by the Ministry of Health, Labour and Welfare. It is intended to facilitate safer use of pharmaceuticals and medical devices by healthcare providers. PMDSI is available on the Pharmaceuticals and Medical Devices Agency website (http://www.pmda.go.jp/english/index.html) and on the MHLW website (http://www.mhlw.go.jp/, Japanese only). Published by Translated by Pharmaceutical and Food Safety Bureau, Pharmaceuticals and Medical Devices Agency Ministry of Health, Labour and Welfare Pharmaceutical and Food Safety Bureau, Office of Safety, Ministry
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,821,928 B2 Hemmingsen Et Al
    US008821928B2 (12) United States Patent (10) Patent No.: US 8,821,928 B2 Hemmingsen et al. (45) Date of Patent: Sep. 2, 2014 (54) CONTROLLED RELEASE 5,869,097 A 2/1999 Wong et al. PHARMACEUTICAL COMPOSITIONS FOR 6,103,261 A 8, 2000 Chasin et al. 2003.01.18641 A1 6/2003 Maloney et al. PROLONGED EFFECT 2003/O133976 A1* 7/2003 Pather et al. .................. 424/466 2004/O151772 A1 8/2004 Andersen et al. (75) Inventors: Pernille Hoyrup Hemmingsen, 2005.0053655 A1 3/2005 Yang et al. Bagsvaerd (DK); Anders Vagno 2005/O158382 A1* 7/2005 Cruz et al. .................... 424/468 2006, O1939 12 A1 8, 2006 KetSela et al. Pedersen, Virum (DK); Daniel 2007/OOO3617 A1 1/2007 Fischer et al. Bar-Shalom, Kokkedal (DK) 2007,0004797 A1 1/2007 Weyers et al. (73) Assignee: Egalet Ltd., London (GB) 2007. O190142 A1 8, 2007 Breitenbach et al. (Continued) (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 FOREIGN PATENT DOCUMENTS U.S.C. 154(b) by 1052 days. DE 202006O14131 1, 2007 EP O435,726 8, 1991 (21) Appl. No.: 12/602.953 (Continued) (22) PCT Filed: Jun. 4, 2008 OTHER PUBLICATIONS (86). PCT No.: PCT/EP2008/056910 Krogel etal (Pharmaceutical Research, vol. 15, 1998, pp. 474-481).* Notification of Transmittal of the International Search Report and the S371 (c)(1), Written Opinion of the International Searching Authority issued Jul. (2), (4) Date: Jun. 7, 2010 8, 2008 in International Application No. PCT/DK2008/000016. International Preliminary Reporton Patentability issued Jul.
    [Show full text]
  • Experience with 5% Ethanolamine Oleate for Sclerotherapy of Oral Vascular Anomalies: a Cohort of 15 Consecutive Patients*
    Journal of Cranio-Maxillo-Facial Surgery 47 (2019) 106e111 Contents lists available at ScienceDirect Journal of Cranio-Maxillo-Facial Surgery journal homepage: www.jcmfs.com Experience with 5% ethanolamine oleate for sclerotherapy of oral vascular anomalies: A cohort of 15 consecutive patients* * Camila de Nazare Alves de Oliveira Kato a, , Michel Campos Ribeiro b, Marcio Bruno Figueiredo do Amaral c, Soraya de Mattos Camargo Grossmann d, Maria Cassia Ferreira de Aguiar a, Ricardo Alves Mesquita a a Department of the Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil b Department of Oral and Maxillofacial Surgery, Hospital Marcio Cunha, Ipatinga, Minas Gerais, Brazil c Department of Oral and Maxillofacial Surgery, Hospital Joao~ XXIII/FHEMIG, Belo Horizonte, Brazil d Department of Oral Pathology, Pontifical Catholic University of Minas Gerais (PUC Minas), Belo Horizonte, Minas Gerais, Brazil article info abstract Article history: Purpose: To describe the effectiveness and safety of a sclerotherapy protocol with 5% ethanolamine Paper received 5 July 2018 oleate (EO) at 0.1 mL/3 mm for oral vascular anomalies (OVAs). Our hypothesis is that EO applied at a Accepted 9 November 2018 concentration of 5% may decrease the number of sessions necessary for clinical healing. Available online 16 November 2018 Materials and methods: We describe a cohort of 15 consecutive patients. OVAs <20 mm were included. Clinical data of the OVAs were collected. Descriptive and bivariate statistical analyses were performed. Keywords: Results: Fifteen of the 19 OVAs were varicosities and the lower lip was the most affected site (n ¼ 7). The Ethanolamine median size was 6 mm, and one session was required in 89.5% of cases for clinical healing within 28 days.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, following to be employed in commercial fishing or the commercial UST, MXT, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Special Care Advocates in Dentistry 2012 Lit. Review  (SAID’S Search of Dental Literature Published in Calendar Year 2011*)
    2012 ANNUAL SEMINAR RALEIGH, NORTH CAROLINA Special Care Advocates in Dentistry 2012 Lit. Review (SAID’s Search of Dental Literature Published in Calendar Year 2011*) Compiled by: Dr. Robert G. Henry Dr. Douglas Veazey Special Acknowledgement to Ms. Sandy Challman who provided computer support, literature searches, and collecting and compiling the final articles which are seen here. Without her help and support this review would not have been possible. 1 2012 SAID Literature Review – Annual Seminar Raleigh, North Carolina Recent journal articles related to oral health care for people with mental and physical disabilities. Search Program = PubMed Database = Medline Journal Subset = Dental Publication Timeframe = Calendar Year 2011* Language = English SAID Search-Term Results = 5,065 Initial Selection Result = 525 articles Final Selection Result = 219 articles SAID Search-Terms Employed: 1. Intellectual disability 22. Protective devices 2. Mental retardation 23. Moderate sedation 3. Mental deficiency 24. Conscious sedation 4. Mental disorders 25. Analgesia 5. Mental health 26. Anesthesia 6. Mental illness 27. Dental anxiety 7. Dental care for disabled 28. Nitrous oxide 8. Dental care for chronically ill 29. Gingival hyperplasia 9. Self-mutilation 30. Gingival hypertrophy 10. Disabled 31. Glossectomy 11. Behavior management 32. Sialorrhea 12. Behavior modification 33. Bruxism 13. Behavior therapy 34. Deglutition disorders 14. Cognitive therapy 35. Community dentistry 15. Down syndrome 36. State dentistry 16. Cerebral palsy 37. Gagging 17. Epilepsy 38. Substance abuse 18. Enteral nutrition 39. Syndromes 19. Physical restraint 40. Tooth brushing 20. Immobilization 41. Pharmaceutical preparations 21. Pediatric dentistry 42. Public health dentistry Program: EndNote X3 used to organize search and provide abstract.
    [Show full text]
  • Pharmaabkommen A1 E
    Annex I - Pharmaceutical substances, which are free of duty_______________________________________________ Pharmaceutical substances which are Annex I free of duty CAS RN Name 136470-78-5 abacavir 129639-79-8 abafungin 792921-10-9 abagovomab 65195-55-3 abamectin 90402-40-7 abanoquil 183849-43-6 abaperidone 183552-38-7 abarelixe 332348-12-6 abatacept 143653-53-6 abciximab 111841-85-1 abecarnil 167362-48-3 abetimus 154229-19-3 abiraterone 137882-98-5 abitesartan 96566-25-5 ablukast 178535-93-8 abrineurin 91017-58-2 abunidazole 2627-69-2 acadesine 77337-76-9 acamprosate 55485-20-6 acaprazine 56180-94-0 acarbose 514-50-1 acebrochol 26976-72-7 aceburic acid 37517-30-9 acebutolol 32795-44-1 acecainide 77-66-7 acecarbromal 827-61-2 aceclidine 89796-99-6 aceclofenac 77-46-3 acedapsone 127-60-6 acediasulfone sodium 556-08-1 acedoben 80595-73-9 acefluranol 10072-48-7 acefurtiamine 70788-27-1 acefylline clofibrol 18428-63-2 acefylline piperazine 642-83-1 aceglatone 2490-97-3 aceglutamide 110042-95-0 acemannan 53164-05-9 acemetacin 131-48-6 aceneuramic acid 152-72-7 acenocoumarol 807-31-8 aceperone 61-00-7 acepromazine 13461-01-3 aceprometazine 42465-20-3 acequinoline 33665-90-6 acesulfame 118-57-0 acetaminosalol 97-44-9 acetarsol 59-66-5 acetazolamide 3031-48-9 acetergamine 299-89-8 acetiamine 2260-08-4 acetiromate 968-81-0 acetohexamide 546-88-3 acetohydroxamic acid 2751-68-0 acetophenazine 1 / 135 (As of: 1.4.2013) Annex I - Pharmaceutical substances, which are free of duty_______________________________________________ CAS RN Name 25333-77-1 acetorphine
    [Show full text]
  • Scheduling of Medicines) GN
    Tanzania Food, Drugs and Cosmetics (Scheduling of Medicines) GN. No. 63 (Contd.) GOVERNMENT NOTICE No. 63 published on 27/02/2015 THE TANZANIA FOOD, DRUGS AND COSMETICS ACT, (CAP. 219) _______ REGULATIONS ________ (Made under Section 122 (1) (y))and 77(2) ________ THE TANZANIA FOOD, DRUGS AND COSMETICS (SCHEDULING OF MEDICINES) REGULATIONS, 2015 ________ ARRANGEMENT OF REGULATIONS Regulation Title PART I PRELIMINARY PROVISIONS 1. Citation and commencement. 2. Application and scope. 3. Interpretation. PART II LIST OF SCHEDULLING OF MEDICINES 4. Restrictions of Scheduling of Medicines. 5. Schedules of human and Veterinary Medicines. 6. Powers to change or vary the scheduling of medicines. 7. Medicines registered after commencement date. 8. Complience to the rules of scheduling of medicines. 1 Tanzania Food, Drugs and Cosmetics (Scheduling of Medicines) GN. No. 63 (Contd.) 9. Banned or recognition of banned medicines. 10. First Schedule Rules for Scheduling of medicines. 11. Second Schedule List of Schedulling of Medicines. 12. Importation of medicines under schedule. 13. Dealers of Mecinens. 14. Narcotic drugs and substances. 15. Narcotic drugs in their original form. 16. Psychotropic substances with limited medical values. 17. Psychotropic drugs with moderate or high therapeutic values. 18. Precursors used in the manufacturing of controlled drugs. 19. Prescription only human medicines. 20. Radiopharmaceuticals. 21. Pharmacy Only Medicines, behind the counter human medicines. 22. Controlled Veterinary Drugs. 23. Keeping of relevant information. 24. Storage of medicine. 25. Prescription only veterinary medicines. 26. Stocked of veterinary Medicine. 27. Pharmacy only veterinary medicines. 28. General sales veterinary medicines. 29. ADDO veterinary medicines _______ SCHEDULES _______ 2 Tanzania Food, Drugs and Cosmetics (Scheduling of Medicines) GN.
    [Show full text]